Severe Coronavirus disease (COVID)-19: from pathogenesis to therapy

Jean-Marc Cavaillon, Antonio Artigas, Andreas Barratt-Due, Evangelos J. Giamarellos-Bourboulis, Hernando Gómez, Gilles Hayem, Alexander P. J. Vlaar, W. Joost Wiersinga

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

The COVID-19 pandemic has been a challenge to propose efficient therapies. Because severe SARS-CoV2 infection is a viral sepsis eventually followed by an immunological autoinflammatory phenomenon, many approaches have been inspired by the previous attempts made in bacterial sepsis, while specific antiviral strategies (use of interferon or specific drugs) have been additionally investigated. We summarize our current thinking on the use of SARS-CoV-2 antivirals, corticosteroids, anti-IL-1, anti-IL-6, anti-C5a, as well as stem cell therapy in severe COVID-19. Patient stratification and appropriate time window will be important to be defined to guide successful treatment.
Original languageEnglish
Pages (from-to)10-15
Number of pages6
JournalShock (Augusta, Ga.)
Volume59
Issue number3
Early online date23 Jul 2022
DOIs
Publication statusPublished - 1 Mar 2023

Cite this